Clinical Trials Browser

Phase 2 × Recurrence × fluzoparib × Clear all

NCT06413992 2024-05-14

Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer

Phase 2 Recruiting

Neoplasm Metastasis, Recurrence, Endometrial Neoplasms